U.S. Markets closed

CASI Pharmaceuticals, Inc. (CASI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7700+0.1700 (+10.62%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6000
Open1.7000
Bid1.7500 x 1800
Ask1.7900 x 1300
Day's Range1.6500 - 1.8600
52 Week Range1.1500 - 3.5700
Volume1,002,673
Avg. Volume423,809
Market Cap219.381M
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)-0.4030
Earnings DateNov 10, 2020 - Nov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.20
  • CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting
    PR Newswire

    CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting

    CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that research conducted at the New York Blood Center investigating the impact of CID-103 on RBC pretransfusion test methods, will be presented at the American Association of Blood Banks (AABB) Virtual Annual Meeting being held October 3-5, 2020.

  • CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd
    PR Newswire

    CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd

    CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced a restructuring of its partnership with Juventas Cell Therapy Ltd. relating to CNCT19, an investigational CD19 CAR-T Cell therapy. Juventas is currently developing CNCT19 for the treatment of patients with relapsed B-cell Non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia, and expects to initiate registration trials in early 2021.

  • CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences
    PR Newswire

    CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences

    CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the following upcoming virtual conferences in September. Details for the virtual conferences are as follows.